- Home
- DDI vs BCYC Comparison
DDI vs BCYC Comparison
Compare DDI & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DDI
- BCYC
- Stock Information
- Founded
- DDI 2008
- BCYC 2009
- Country
- DDI South Korea
- BCYC United Kingdom
- Employees
- DDI N/A
- BCYC N/A
- Industry
- DDI EDP Services
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- DDI Technology
- BCYC Health Care
- Exchange
- DDI Nasdaq
- BCYC Nasdaq
- Market Cap
- DDI 480.7M
- BCYC 566.5M
- IPO Year
- DDI 2021
- BCYC 2019
- Fundamental
- Price
- DDI $9.21
- BCYC $7.99
- Analyst Decision
- DDI Strong Buy
- BCYC Buy
- Analyst Count
- DDI 5
- BCYC 11
- Target Price
- DDI $19.60
- BCYC $25.00
- AVG Volume (30 Days)
- DDI 52.9K
- BCYC 277.2K
- Earning Date
- DDI 08-12-2025
- BCYC 08-12-2025
- Dividend Yield
- DDI N/A
- BCYC N/A
- EPS Growth
- DDI 9.79
- BCYC N/A
- EPS
- DDI 2.37
- BCYC N/A
- Revenue
- DDI $336,679,000.00
- BCYC $25,722,000.00
- Revenue This Year
- DDI $8.79
- BCYC $7.35
- Revenue Next Year
- DDI $2.04
- BCYC N/A
- P/E Ratio
- DDI $3.88
- BCYC N/A
- Revenue Growth
- DDI 5.41
- BCYC N/A
- 52 Week Low
- DDI $8.09
- BCYC $6.10
- 52 Week High
- DDI $18.21
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- DDI 36.21
- BCYC 46.46
- Support Level
- DDI $9.51
- BCYC $8.40
- Resistance Level
- DDI $9.77
- BCYC $8.88
- Average True Range (ATR)
- DDI 0.29
- BCYC 0.50
- MACD
- DDI -0.06
- BCYC -0.00
- Stochastic Oscillator
- DDI 7.62
- BCYC 24.40
About DDI DoubleDown Interactive Co. Ltd. American Depository Shares
DoubleDown Interactive Co Ltd is a developer and publisher of digital games on mobile and web-based platforms. The company is the creator of multi-format interactive entertainment experiences for casual players. The company's operating segments include the social casino games segment and the iGaming segment. The company generates the majority of its revenue from social casino games. Geographically, the company generates the majority of its revenue from the United States.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.